Regeneron Pharmaceuticals, Inc.
Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Variants And Uses Thereof
Last updated:
Abstract:
Methods of treating obesity and methods of identifying susceptibility of an obese subject to treatment with an agonist of the leptin-melanocortin signaling pathway are provided herein.
Status:
Application
Type:
Utility
Filling date:
3 May 2021
Issue date:
18 Nov 2021